1141 Total polyunsaturated fatty acid level in adipose tissue as an independent predictor of recurrence-free survival in women with ovarian cancer

Introduction/Background* Prognostic factors for epithelial ovarian cancers (EOCs) are in particular clinical factors such as pathology staging at diagnosis (FIGO stages), genetic mutation or histological phenotypes. In the present study, we explored whether fatty acid composition of adipose tissue, may be associated with recurrence-free survival in EOC. Methodology Forty-six women with epithelial ovarian cancers and 6 with borderline ovarian tumors were included between March 2017 and January 2020 in this prospective study in Tours university teaching hospital (central France). Adipose tissue specimens from four abdominal locations (superficial and deep subcutaneous, visceral epiploic and omental) were collected during surgery or exploratory laparoscopy. A fatty acid profile of adipose tissue triglycerides was established by gas chromatography. We assessed differences associated with disease recurrence. Result(s)* The content of long-chain saturated fatty acids (SFAs) was increased and that of long-chain polyunsaturated fatty acids (PUFAs) decreased in deep versus superficial subcutaneous adipose tissue in EOC patients. Nevertheless, the content of total SFAs was 28%, monounsaturated fatty acids (MUFAs) 55%, PUFAs n-6 11.5% and PUFAs n-3 about 1.3% whatever the adipose tissue. For EOC patients, median follow-up was 15 months. FIGO stage, tumor residue after surgery and body mass index, were clinical predictors of recurrence-free survival (RFS). EOC patients were separated into two groups by median fatty acid content. Content of total PUFAs (n-6+n-3), whatever the adipose tissue, was associated with RFS. RFS was about 2 times longer in EOC patients with high versus low total PUFA content (median survival: 12 vs 27 months, p = 0.01 to Conclusion* Content of total PUFAs (n-6+n-3) in abdominal adipose tissue (visceral and subcutaneous) are new prognostic factors in EOC. The origin of PUFAs depletion needs to be explored, to design a new therapeutic strategy for these patients